Premium
Enhancement of DNA vaccine potency through linkage of antigen to filamentous bacteriophage coat protein III domain I
Author(s) -
Cuesta Ángel M.,
Suárez Eduardo,
Larsen Martin,
Jensen Kim Bak,
Sanz Laura,
Compte Marta,
Kristensen Peter,
ÁlvarezVallina Luis
Publication year - 2006
Publication title -
immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.297
H-Index - 133
eISSN - 1365-2567
pISSN - 0019-2805
DOI - 10.1111/j.1365-2567.2006.02325.x
Subject(s) - coat protein , bacteriophage , coat , potency , dna , antigen , biology , microbiology and biotechnology , virology , filamentous bacteriophage , genetics , gene , escherichia coli , in vitro , paleontology , rna
Summary Although DNA‐based cancer vaccines have been successfully tested in mouse models, a major drawback of cancer vaccination still remains, namely that tumour antigens are weak and fail to generate a vigorous immune response in tumour‐bearing patients. Genetic technology offers strategies for promoting immune pathways by adding immune‐activating genes to the tumour antigen sequence. In this work, we converted a model non‐immunogenic antigen into a vaccine by fusing it to domain I of the filamentous bacteriophage coat protein III gene. Vaccination with a DNA construct encoding the domain I fusion generated antigen‐specific T helper 1‐type cellular immune responses. These results demonstrate that the incorporation of protein III into a DNA vaccine formulation can modulate the gene‐mediated immune response and may thus provide a strategy for improving its therapeutic effect.